Wall Street Zen Downgrades Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) to Strong Sell

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) was downgraded by stock analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report issued on Saturday.

Separately, Weiss Ratings began coverage on Lakewood-Amedex Biotherapeutics in a research report on Monday, July 20th. They set a “sell (e-)” rating for the company. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Lakewood-Amedex Biotherapeutics Price Performance

LABT opened at $2.30 on Friday. The firm’s fifty day moving average price is $2.54. The stock has a market cap of $5.45 million and a price-to-earnings ratio of -0.48. Lakewood-Amedex Biotherapeutics has a one year low of $1.66 and a one year high of $98.20.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) last posted its quarterly earnings data on Friday, August 14th. The company reported ($2.75) earnings per share (EPS) for the quarter. Research analysts forecast that Lakewood-Amedex Biotherapeutics will post 2.52 earnings per share for the current year.

Lakewood-Amedex Biotherapeutics Company Profile

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.